The Anatara team met senior business journalist Tim Boreham from The Australian newspaper recently to brief him on Anatara and our plans. He notes we’re raising $7 million from investors and that we’re intending to conduct new trials to get Detach re-registered in Australia. He suggests people read our prospectus when it’s lodged.
Anatara’s chief scientific officer Dr Tracey Mynott was interviewed by ABC Radio Brisbane about how DetachTM was created and how treating diarrhoea in pigs could lead to treatments for humans.
To listen to the interview, click here.
By Dylan Bushell-Embling, Australian Life Scientist
Anatara Lifesciences used this week’s BIO International Convention to pursue distribution and development partners for Detach, its new non-antibiotic treatment for diarrhoea.
The company is pursuing commercialisation for the product in pigs first and subsequently plans to expand its use to other livestock and develop the treatment for use in humans.
Detach works by stopping bacteria from attaching to the lining of the intestine, as well as blocking the action of their toxins.
Anatara CEO Dr David Venables said there is a strong market opportunity for Detach in light of growing consumer demand for antibiotic-free food and concerns over antibiotic-resistant “superbugs”.
“The World Health Organization has warned that antimicrobial resistance is a significant looming threat to human health and authorities are now moving to tackle the issue by limiting the use of antibiotics in animal agriculture,” he said.
The article can be found here.
BRISBANE, June 24, 2014: Anatara Lifesciences, a company developing non-antibiotic treatments for gastrointestinal diseases in animals and humans, will be seeking distribution and development partners at the world’s largest biotechnology conference in the United States this week.
The company will be presenting at the 2014 BIO International Convention in San Diego and introducing to thousands of attendees its lead product Detach™, a non-antibiotic treatment for diarrhoea.
Anatara CEO Dr David Venables says the company is addressing a significant global problem around the rise of antimicrobial resistance and so-called “superbugs” caused by the overuse of antibiotics in production animals and humans.
“The World Health Organization has warned that antimicrobial resistance is a significant looming threat to human health and authorities are now moving to tackle the issue by limiting the use of antibiotics in animal agriculture,” Dr Venables says.
Anatara, which raised $1.75 million in a private placing earlier this year, is currently focused on commercialising Detach™ for use in pigs ahead of expanding its use to other livestock and then developing it for use in humans.
“Detach™ is a proven, natural treatment for diarrhoea in piglets and is an effective alternative to antibiotics,” Dr Venables says.
Anatara’s Chairman, life science industry veteran Mel Bridges, says that growing consumer demand for antibiotic-free food will make Detach™ an attractive product for livestock farmers.
“We have a unique value proposition to enter a market that’s worth billions of dollars every year,” he says.
Anatara Chief Science Officer Dr Tracey Mynott, who was one of the creators of Detach™, says the medicine works against bacteria, viruses and other causes of diarrhoea.
“Detach™ acts by stopping bacteria from attaching to the lining of the intestine, as well as blocking the action of their toxins, the underlying cause of diarrhoea. It works differently to antibiotics in that it doesn’t try to kill bacteria and instead lets them pass through the intestine harmlessly.”
While at the BIO International Convention, Anatara will seek partnering opportunities with animal health companies to distribute Detach™ around the world. It will also seek partners to develop the medicine for human use.
The United Kingdom’s Royal Pharmaceutical Society has recommended better stewardship in the use of antibiotics be encouraged in the wake of growing international concerns about the rise of antimicrobial resistance.
The recommendation is one of seven the society makes in a report discussing challenges around developing new medicines, improving existing medicines and making better use of the ones already available.
“The increasing development of resistance to currently available antibiotics is a potentially serious threat to public health,” the report, titled New Medicines, Better Medicines, Better Use of Medicines, says.
It says the “profound consequences of antibiotic resistance for individual patients and for society create an ethical and moral imperative to protect public health by all reasonable means”.
Two leaders in human health have called for the
creation of a global organisation to tackle the growing threat of
Mark Woolhouse, professor of infectious disease
epidemiology in the Centre for Immunity, Infection & Evolution at
the University of Edinburgh, and Jeremy Farrar, director of the global
health charity Wellcome Trust, have written in Nature seeking a
organisation similar to the Intergovernmental Panel on Climate Change.
“What is required is committed and coordinated action
on the root causes of resistance: the misuse of antimicrobials, the
paucity of development of new drugs and the lack of alternatives,”
“Guidelines must be implemented to improve the use of existing drugs;
the scientific and business worlds need incentives and a better
regulatory environment to develop new drugs and approaches, and those
working in both the animal and human sectors need education and
incentives to help them to change their ways.” Read more »
US regulators say 25 out of 26 drug makers that sell antibiotics used in livestock feed for growth enhancement have agreed to follow new guidelines that will make it illegal to use their products to create bigger animals. Read more »
The US Food and Drug Administration updates the animal pharmaceutical industry’s response to its plan to help phase out the use of medically important antimicrobials in food animals for food production purposes. Read more »
Lance Price is a public health researcher who works at the interface between science and policy to address the growing crisis of antibiotic resistance. To view his talk, delivered on March 11, 2014 in Manhattan, click here.
Policy-makers reacting the rise in bacteria resistant to antiobiotics.Read more »